Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling

The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease

(2021) Stefano Fiorucci et al.   Expert Opinion on Drug Discovery

Targeting inflammation in atherosclerosis — from experimental insights to the clinic

(2021) Oliver Soehnlein et al.   NATURE REVIEWS DRUG DISCOVERY

Bile acids and their receptors in metabolic disorders

(2021) Stefano Fiorucci et al.   PROGRESS IN LIPID RESEARCH

Muricholic Acids Promote Resistance to Hypercholesterolemia in Cholesterol-Fed Mice

(2021) Dany Gaillard et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol

(2021) James M. Eng et al.   Cells

Of mice and men: Murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism

(2020) Sara Straniero et al.   JOURNAL OF LIPID RESEARCH

Is CYP2C70 the key to new mouse models to understand bile acids in humans?

(2020) Grace L. Guo et al.   JOURNAL OF LIPID RESEARCH

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)

(2020) Stefano Fiorucci et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy

(2020) Adriana Carino et al.   FASEB JOURNAL

Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome

(2019) Ziwei Song et al.   Microbiome

FRI-037-Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort

(2019) Cynthia Levy et al.   JOURNAL OF HEPATOLOGY

Nonalcoholic Fatty Liver Disease and the Incidence of Myocardial Infarction: A Cohort Study

(2019) Dong Hyun Sinn et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A Human-like Bile Acid Pool Induced by Deletion of Cyp2c70 Modulates Effects of Farnesoid X Receptor Activation in Mice

(2019) Jan Freark de Boer et al.   JOURNAL OF LIPID RESEARCH

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

(2019) Paul J. Pockros et al.   LIVER INTERNATIONAL

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults

(2019) Myriam Alexander et al.   BMJ-British Medical Journal

Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease

(2019) Gordon I. Smith et al.   JOURNAL OF CLINICAL INVESTIGATION

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Bile acids in glucose metabolism in health and disease

(2018) Hagit Shapiro et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

(2018) Chris Estes et al.   JOURNAL OF HEPATOLOGY

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

(2018) Amedeo Lonardo et al.   JOURNAL OF HEPATOLOGY

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Future trends in the treatment of non-alcoholic steatohepatitis

(2018) Stefano Fiorucci et al.   PHARMACOLOGICAL RESEARCH

Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis

(2018) Adriana Carino et al.   FASEB JOURNAL

Animal models of atherosclerosis

(2017) Besa Emini Veseli et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

(2017) Jan Freark de Boer et al.   GASTROENTEROLOGY

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

(2017) Chris Estes et al.   HEPATOLOGY

The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis

(2017) Michele Biagioli et al.   JOURNAL OF IMMUNOLOGY

Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice

(2017) Adriana Carino et al.   Scientific Reports

G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice

(2016) Ajay C. Donepudi et al.   HEPATOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans

(2016) Shogo Takahashi et al.   JOURNAL OF LIPID RESEARCH

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity

(2016) Valentina Sepe et al.   STEROIDS

Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists

(2016) Valentina Sepe et al.   Scientific Reports

Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids

(2015) Barbara Renga et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes

(2015) Na Fang et al.   MEDICINE

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

(2015) Changtao Jiang et al.   Nature Communications

TGR5: Pathogenetic Role and/or Therapeutic Target in Fibrosing Cholangitis?

(2014) Verena Keitel et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Meta-analyses of human gut microbes associated with obesity and IBD

(2014) William A. Walters et al.   FEBS LETTERS

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands

(2014) Carmen Festa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1)

(2014) Valentina Sepe et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bile Acid Receptor TGR5 Agonism Induces NO Production and Reduces Monocyte Adhesion in Vascular Endothelial Cells

(2013) Taiki Kida et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist

(2013) Sama I. Sayin et al.   Cell Metabolism

Dissociation of Intestinal and Hepatic Activities of FXR and LXR  Supports Metabolic Effects of Terminal Ileum Interposition in Rodents

(2013) A. Mencarelli et al.   DIABETES

Regulation of cholesterol and bile acid homeostasis by the cholesterol 7α-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice

(2013) Tiangang Li et al.   HEPATOLOGY

Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity

(2013) Fei Li et al.   Nature Communications

Differences in gut microbiota composition between obese and lean children: a cross-sectional study

(2013) Liene Bervoets et al.   Gut Pathogens

Animal Models of Atherosclerosis

(2012) Godfrey S. Getz et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Correlation of intestinal microbiota with overweight and obesity in Kazakh school children

(2012) Peiru Xu et al.   BMC MICROBIOLOGY

Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway

(2012) Riko Ichikawa et al.   IMMUNOLOGY

Effect of Statin Therapy on the Progression of Common Carotid Artery Intima-Media Thickness: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2012) Yubei Huang et al.   Journal of Atherosclerosis and Thrombosis

Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans

(2011) Reiner Jumpertz et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter

(2011) Barbara Renga et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading

(2011) Thijs W.H. Pols et al.   Cell Metabolism

The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis

(2011) Sabrina Cipriani et al.   PLoS One

Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice

(2010) Galya Vassileva et al.   JOURNAL OF ENDOCRINOLOGY

The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders

(2009) Verena Keitel et al.   HEPATOLOGY

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

Bile acids: regulation of synthesis

(2009) John Y. L. Chiang   JOURNAL OF LIPID RESEARCH

Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism

(2009) Mary-Elizabeth Patti et al.   Obesity

Antiatherosclerotic effect of farnesoid X receptor

(2008) Andrea Mencarelli et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Expression and function of the bile acid receptor TGR5 in Kupffer cells

(2008) Verena Keitel et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression

(2008) Kwang-Hoon Song et al.   HEPATOLOGY

Endocrine and paracrine role of bile acids

(2008) Verena Keitel et al.   WORLD JOURNAL OF GASTROENTEROLOGY